REFERENCES
1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved
Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res. 2020:104787.
2. Solomon S. FDA Letter to Stakeholders: Do Not Use Ivermectin Intended
for Animals as Treatment for COVID-19 in Humans. 2020;https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans.
Accessed April 15th, 2020.
3. Smith PF, Dodds M, Bentley D, Yeo K, Rayner C. Dosing will be a key
success factor in repurposing antivirals for COVID-19. Br J Clin
Pharmacol. 2020.
4. Smit MR, Ochomo EO, Waterhouse D, et al.
Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with
Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and
QT-Prolongation (IVERMAL). Clin Pharmacol Ther.2019;105(2):388-401.
5. Duthaler U, Suenderhauf C, Karlsson MO, et al. Population
pharmacokinetics of oral ivermectin in venous plasma and dried blood
spots in healthy volunteers. Br J Clin Pharmacol.2019;85(3):626-633.
6. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and
pharmacokinetics of escalating high doses of ivermectin in healthy adult
subjects. J Clin Pharmacol. 2002;42(10):1122-1133.
7. Yamasmith E, Saleh-arong FA, Avirutnan P, et al. Efficacy and Safety
of Ivermectin against Dengue Infection: A Phase III, Randomized,
Double-blind, Placebo-controlled Trial. The 34th Annual Meeting The
Royal College of Physicians of Thailand; April, 2018, 2018; PEACH Royal
Cliff Beach Resort, Pattaya, Chonburi, Thailand